Skip to content

Potassium Titanyl Phosphate Laser Versus Pulsed Dye Laser for Rosacea - a Prospective Study

Potassium Titanyl Phosphate Laser Versus Pulsed Dye Laser for Rosacea - a Prospective Case-Control Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05771298
Enrollment
30
Registered
2023-03-16
Start date
2023-02-01
Completion date
2023-06-01
Last updated
2023-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Brief summary

To compare the efficacy and safety of 532 nm KTP and 585 nm PDL for treating rosacea.

Detailed description

Rosacea is a common, chronic inflammatory skin disease that usually affects the cheeks, nose, forehead, and chin \[1\]. Clinically, it presents initially with transient erythema (flushing) and telangiectasia. As it progresses, persistent erythema and papules and pustules appear. Phymatous changes result from hypertrophy of the sebaceous glands, and usually manifest as rhinophyma, gnatophyma, and metophyma \[2\]. Depending on the literature, rosacea has a prevalence of 1% to 22% \[3\]. Time of manifestation of the disease is usually between 30 and 50 years \[4\]. Women are more frequently affected \[4\]. For laser treatment of rosacea, the pulsed dye laser (PDL) with a wavelength of 595nm is frequently used. The treatment includes at least three sessions at intervals of about 4 weeks and leads to lightening and reduction of the lesions as well as reduction of papules and pustules. Various clinical studies have already demonstrated the high efficacy of PDL \[5-7\]. The treatment is painless, and local or general anesthesia is not necessary. The KTP laser is also an option in the treatment of rosacea. Due to the more stable technology of the frequency-doubled Nd:YAG (KTP) and associated lower maintenance problems, this laser system appears to be a safer and more reliable treatment option for rosacea patients.

Interventions

DEVICE532nm KTP

one to three treatment sessions

DEVICE585nm PDL

one to three treatment sessions

Sponsors

Universitätsklinikum Hamburg-Eppendorf
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and women 18 years and older * Good general health, no relevant previous diseases * Presence of rosacea * Cognitive ability and willingness to give consent (Informed Consent)

Exclusion criteria

* Age \< 18 years * Pregnant and breastfeeding women * Significant open wounds or lesions of the region to be treated * Metallic implants in the region to be treated * Missing consent and/or data protection declarations

Design outcomes

Primary

MeasureTime frameDescription
pain intensityat follow-up visit 4 weeks after last treatment sessionusing numeric rating scale 0 - 10 (none - unbearable pain) evaluated by subjects
reduction of erythemaat follow-up visit 4 weeks after last treatment sessionassessment scale 0 - 4 (normal skin - severe erythema) evaluated by physician and blinded investigator
swellingat follow-up visit 4 weeks after last treatment sessionassessment scale 1 - 6 (very - none) evaluated by subjects
purpuraat follow-up visit 4 weeks after last treatment sessionassessment scale 1 - 6 (very - none) evaluated by subjects

Secondary

MeasureTime frameDescription
patient satisfactionat follow-up visit 4 weeks after last treatment sessionassessment scale 1 - 6 (very - not at all) evaluated by subjects

Countries

Germany

Contacts

Primary ContactL Nguyen, MD
l.nguyen@uke.de+49 (0)40 7410-0

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026